Scaling AAV9 Manufacturing: A Blueprint for Clinical-Grade Gene Therapy Production
May 02, 2026
Scalable AAV manufacturing is one of the most persistent bottlenecks in gene therapy. High viral titers through triple...
Read more →Artis Publications
At Advanced Therapies Week 2026, our Chief Technology Officer, Gregg Nyberg, joined a panel of industry leaders to discuss how advanced therapy developers are navigating the path...
Read More →May 02, 2026
Scalable AAV manufacturing is one of the most persistent bottlenecks in gene therapy. High viral titers through triple...
Read more →May 02, 2026
Moving stem cell programs toward GMP manufacturing requires navigating a complex set of process dependent factors that influence...
Read more →